Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Ultragenyx Pharmaceutical

Explore full profile

Treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases

Novato, United StatesFounded 2010Biotech & Life Sciences
Valuation $1.81B Market cap · Aug/2026
Revenue $748M Latest reported FY

At a glance

Status
Listed
Founded
2010
Headquarters
Novato, United States
Listing
IPO 2014
Sector
Biotech & Life Sciences
Power Law
Unicorn$1–10B valuation tierThoroughbred$100M+ revenue

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom
News
News Probably Genetic lands $12M Series A to turn rare disease data into drug targets Oct 14, 2026

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • Takeda Ventures
  • TPG

Series B and later5 investors entered at this stage

Talent

Book a demo to see the people
Employees mapped 1,531 incl. 1 AI specialist
Founders Hidden — book a demo/100 quality score
Key operators 26 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
21 countries with
team presence
🇺🇸 United States83.2%
🇧🇷 Brazil3.9%
🇨🇭 Switzerland2.6%
🇲🇽 Mexico1.5%
🇦🇷 Argentina1.4%
Top 5 of 21 shown
Web traffic by country
24K monthly visits
across markets
🇺🇸 United States56.7%
🇮🇳 India12.5%
🇯🇵 Japan8.3%
🇲🇽 Mexico7.1%
🇬🇧 United Kingdom3.8%
Top 5 markets shown

Patents

Estimated portfolio value
$86M

50 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Investments and acquisitions

Disclosed deals where Ultragenyx Pharmaceutical was the backer or acquirer, 2017–2024. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

4 deals across Ultragenyx Pharmaceutical's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        Ultragenyx Pharmaceutical's portfolio, mapped.

        Stage
        Period
        4 of 4 deals

        Market sentiment

        Posts on X, past 7 days

        An AI-synthesised read of the highest-engagement posts about Ultragenyx Pharmaceutical on X, ranked by likes and reposts, corporate channels excluded.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Ultragenyx Pharmaceutical on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

        Book a demo Explore company profiles